Overview

Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to assess the efficacy, safety, and side effects among doses approved by the Food and Drug Administration and higher (not FDA approved) doses of olanzapine in patients with schizophrenia or schizoaffective disorder.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine